Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia

about

Multimeric peptide-based PEG nanocarriers with programmable elimination properties.

P2860

Q43067403-69397711-069E-4217-A95B-16709D3986AE

P2860

Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia

Item

http://www.wikidata.org/entity/Q36025037

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Dose selection and population ...... chronic myelogenous leukaemia

@ast

Dose selection and population ...... chronic myelogenous leukaemia

@en

type

Item

label

Dose selection and population ...... chronic myelogenous leukaemia

@ast

Dose selection and population ...... chronic myelogenous leukaemia

@en

prefLabel

Dose selection and population ...... chronic myelogenous leukaemia

@ast

Dose selection and population ...... chronic myelogenous leukaemia

@en

P1476

Dose selection and population ...... chronic myelogenous leukaemia

@en

P2093

David Cutler

http://www.w3.org/2001/XMLSchema#string

Juif Jen

http://www.w3.org/2001/XMLSchema#string

Karen Kolz

http://www.w3.org/2001/XMLSchema#string

Samir Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Pharmacogenomics: the promise of personalized medicine

Prediction of creatinine clearance from serum creatinine

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Chronic myelogenous leukemia: biology and therapy.

Treatment of myelogenous leukemia: current status and investigational options.

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

P304

292-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2006.02757.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6848237

http://www.w3.org/2001/XMLSchema#string

P698

16939523

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

2000735

http://www.w3.org/2001/XMLSchema#string

Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia

about

P2860

P2860

Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932